MarketPulse

CIDP

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx

argenx to Report Q1 2026 Results; Immunology Firm Signals Strategic Update

argenx will report Q1 2026 financial results on May 7, 2026, offering investors insight into the immunology company's clinical progress and commercial trajectory.
ARGXautoimmune diseasesconference call
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Folia Health

Folia Health and Argenx Partner on Groundbreaking Real-World Evidence Study for CIDP Patients

Folia Health and Argenx launch at-home real-world evidence study capturing CIDP patient symptom data over six months using app-based reporting platform.
ARGXreal-world evidenceCIDP
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus to Unveil Phase 3 CIDP Trial Data as Claseprubart Nears Potential Breakthrough

Dianthus Therapeutics will present interim responder analysis from Phase 3 CAPTIVATE trial of claseprubart for CIDP treatment on March 9, 2026.
DNTHclinical-stage biotechPhase 3 trial